Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
10:00am, Wednesday, 09'th Apr 2025
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
5 Top Growth Stocks to Buy in the Stock Market Sell-Off
10:00am, Wednesday, 09'th Apr 2025
Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tell
Is Vertex Pharmaceuticals Stock a Buy?
09:45am, Tuesday, 08'th Apr 2025
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX 0.75%). Compared to the S&P 500 index, which is down about 16% f
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe
07:55am, Tuesday, 08'th Apr 2025
With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.
Vertex to Announce First Quarter 2025 Financial Results on May 5th
04:05pm, Monday, 07'th Apr 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company w
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
12:11pm, Monday, 07'th Apr 2025
Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx.
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
12:00pm, Monday, 07'th Apr 2025
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/ele
2 Stocks to Buy if You're Worried About a Recession
05:24am, Monday, 07'th Apr 2025
Is a recession coming? Our economic outlook seems increasingly gloomy due to President Trump's trade policies.
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the Storm
05:45am, Sunday, 06'th Apr 2025
Stocks are sinking the most since the COVID-19-fueled sell-off in 2020. A global trade war seems imminent.
Live Nasdaq Composite: FIVE Falls, AZN and PEP Rise From Tariff Ashes
09:30am, Friday, 04'th Apr 2025
The markets have succumbed to the tariff-fueled selling pressure, and there is nowhere to hide. President Trump’s tariff plan is intensifying the trade war. The Dow Jones Industrial is spiraling
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.
04:42am, Friday, 04'th Apr 2025
Which group of individuals is in the best position to spot early warning signs of economic trouble? There's a good case to be made for corporate chief financial officers (CFOs).
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
06:55pm, Thursday, 03'rd Apr 2025
Vertex Pharmaceuticals (VRTX) reachead $484.01 at the closing of the latest trading day, reflecting a +0.11% change compared to its last close.
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
02:01pm, Tuesday, 01'st Apr 2025
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
11:55am, Tuesday, 01'st Apr 2025
Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
04:05pm, Friday, 28'th Mar 2025
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollm
